Human Relaxin-2Check methods and identity
What the Volenrelaxin Trial Revealed About Measuring Congestion
1 numbered sourceSource years 2025
A peptide is an amino-acid chain held together by peptide bonds. It can act as a hormone, and a modified version can behave differently because of how long it stays in circulation. Human relaxin-2 is the hormone that inspired volenrelaxin, a longer-acting investigational molecule. The phase 2 trial discussed here tested volenrelaxin in people with worsening heart failure and preserved ejection fraction, a condition in which the heart can eject a usual proportion of blood while still having difficulty filling or coping with pressure. The original clinical report was published in 2025 and is the direct source for these findings. [1]
Barry Borlaug and colleagues planned to compare several exposure groups with placebo. They assessed how the left atrium, a chamber of the heart, stretches as it receives blood. The primary outcome was change in a measure called left atrial reservoir strain. Secondary measures included a blood marker that can rise when the heart is under stress and an estimate of kidney filtration. The design let the team ask whether changes in heart mechanics aligned with changes in congestion and kidney function. [1]
A low exposure group showed an improvement on the strain measure compared with placebo. Higher groups did not show the same clear difference on that outcome. When the treatment groups were combined for analysis, the blood marker NT-proBNP increased, and there was no clear improvement in the estimate of kidney filtration. The sponsor stopped the trial early after 332 people had enrolled because of evidence of worsening congestion. The report also described imprecise signals involving hospitalization and serious events, which should not be presented as definite estimates of risk. [1]
This study shows why a result can look encouraging on one measurement while still raising a concern overall. A change in how an atrium stretches is an important observation about one aspect of heart function. It does not settle how a patient feels, how often that patient is hospitalized, or whether congestion improves. The evidence concerns volenrelaxin in this particular group, not unmodified human relaxin-2 or all compounds that activate the same receptor. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
